Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1/2 4 Phase 1 3 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Non-Hodgkin 1 Lymphoma 1

Interventions

Rituximab 59 Cyclophosphamide 35 Vincristine 28 Doxorubicin 24 Prednisone 22 Bendamustine Hydrochloride 17 Etoposide 15 Radiotherapy 12 Cytarabine 10 Peripheral Blood Stem Cell Transplantation 8 Filgrastim 8 ibrutinib 7 VAP-cyclo protocol 7 Prednisolone 7 Methotrexate 7 Granulocyte Colony-Stimulating Factor 7 ibritumomab tiuxetan 6 fludarabine 6 Melphalan 6 Gemcitabine 6 pirtobrutinib 5 Mitoxantrone 5 Lenalidomide 5 Carmustine 5 Bleomycin 5 pixantrone 4 Mycophenolic Acid 4 Methylprednisolone 4 Ifosfamide 4 Idarubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Non-Hodgkin × polatuzumab vedotin × Clear all

NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡